UA104517C2 - Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання - Google Patents

Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання

Info

Publication number
UA104517C2
UA104517C2 UAA201211694A UAA201211694A UA104517C2 UA 104517 C2 UA104517 C2 UA 104517C2 UA A201211694 A UAA201211694 A UA A201211694A UA A201211694 A UAA201211694 A UA A201211694A UA 104517 C2 UA104517 C2 UA 104517C2
Authority
UA
Ukraine
Prior art keywords
infection
manufacturing
solid composition
composition useful
treating hepatitis
Prior art date
Application number
UAA201211694A
Other languages
English (en)
Russian (ru)
Inventor
Бернд Ліпольд
Карін Розенблатт
Петер Хеліг
Раджив Гокхале
Ліна Прасад
Джонатан Міллер
Ерік А. Шмітт
Джон Б. Морріс
Original Assignee
Ебботт Леборетріз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ебботт Леборетріз filed Critical Ебботт Леборетріз
Publication of UA104517C2 publication Critical patent/UA104517C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Даний винахід характеризує тверду композицію, що містить аморфну сполуку І з активністю проти вірусу гепатиту С. Тверда дисперсія за даним винаходом містить також фармацевтично прийнятний гідрофільний полімер і фармацевтично прийнятну поверхнево-активну речовину. Сполука І може бути введена до складу аморфної твердої дисперсії, яка містить фармацевтично прийнятний гідрофільний полімер і фармацевтично прийнятну поверхнево-активну речовину.
UAA201211694A 2010-03-10 2011-03-08 Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання UA104517C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33996410P 2010-03-10 2010-03-10
PCT/US2011/027511 WO2011112558A2 (en) 2010-03-10 2011-03-08 Solid compositions

Publications (1)

Publication Number Publication Date
UA104517C2 true UA104517C2 (uk) 2014-02-10

Family

ID=44564075

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201211694A UA104517C2 (uk) 2010-03-10 2011-03-08 Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання

Country Status (27)

Country Link
US (1) US20110312973A1 (uk)
EP (1) EP2544689B1 (uk)
JP (2) JP5717768B2 (uk)
KR (1) KR101579079B1 (uk)
CN (2) CN104771364B (uk)
AR (1) AR081736A1 (uk)
AU (1) AU2011224558B2 (uk)
BR (1) BR112012022774A2 (uk)
CA (1) CA2792601C (uk)
CL (1) CL2012002500A1 (uk)
CO (1) CO6640208A2 (uk)
DO (1) DOP2012000245A (uk)
EA (1) EA021570B1 (uk)
EC (1) ECSP12012148A (uk)
ES (1) ES2613608T3 (uk)
GT (1) GT201200257A (uk)
IL (1) IL221833A (uk)
MX (1) MX2012010478A (uk)
MY (1) MY156888A (uk)
NZ (1) NZ602288A (uk)
PE (1) PE20130198A1 (uk)
SG (1) SG183985A1 (uk)
TW (1) TWI490218B (uk)
UA (1) UA104517C2 (uk)
UY (1) UY33265A (uk)
WO (1) WO2011112558A2 (uk)
ZA (1) ZA201207093B (uk)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2593463T1 (sl) * 2010-07-12 2020-10-30 Salix Pharmaceuticals, Inc. Formulacije rifaksimina in njihove uporabe
KR20140003521A (ko) * 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
US9044480B1 (en) 2011-03-03 2015-06-02 Abbvie Inc. Compositions and methods for treating HCV
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2013040568A1 (en) * 2011-09-16 2013-03-21 Abbvie Inc. Methods for treating hcv
AU2013201758B2 (en) * 2011-10-21 2014-11-27 Abbvie Ireland Unlimited Company Methods for treating HCV
AU2015200715A1 (en) * 2011-10-21 2015-03-05 Abbvie Ireland Unlimited Company Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AU2015100283B4 (en) * 2011-10-21 2015-06-18 Abbvie Ireland Unlimited Company Methods for treating HCV
ES2572355B1 (es) * 2011-10-21 2017-08-24 Abbvie Inc. Combinación de aad para uso en el tratamiento del vhc
WO2013059638A1 (en) * 2011-10-21 2013-04-25 Abbvie Inc. Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
CN103826627B (zh) * 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
JP2015522022A (ja) 2012-06-27 2015-08-03 アッヴィ・インコーポレイテッド Ｈｃｖの処置に使用するためのａｂｔ−４５０およびリトナビルおよび例えばａｂｔ−０７２および／またはａｂｔ−３３３の併用処置
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
NZ630435A (en) * 2012-07-12 2016-11-25 Abbvie Inc Crystalline forms of an hcv inhibitor
WO2014043208A1 (en) * 2012-09-11 2014-03-20 Medivation Prostate Therapeutics, Inc. Formulations of enzalutamide
AU2012392557B2 (en) 2012-10-19 2017-06-01 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105164148A (zh) 2013-03-07 2015-12-16 百时美施贵宝公司 丙型肝炎病毒抑制剂
ES2735355T3 (es) 2013-03-15 2019-12-18 Gilead Sciences Inc Inhibidores macrocíclicos y bicíclicos de virus de hepatitis C
US20150011481A1 (en) 2013-07-02 2015-01-08 Abbvie Inc. Methods for Treating HCV
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
US20150141351A1 (en) * 2013-11-18 2015-05-21 AbbVie Deutschland GmbH & Co. KG Solid Pharmaceutical Compositions
WO2015084953A1 (en) 2013-12-04 2015-06-11 Abbvie Inc. Crystal forms
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US20150209403A1 (en) 2014-01-28 2015-07-30 Abbvie Inc. Dose Adjustment
EP3157569B1 (en) * 2014-06-18 2019-07-24 F.Hoffmann-La Roche Ag New pharmaceutical composition comprising non-ionic surfactants
US20160074462A1 (en) 2014-09-11 2016-03-17 Abbvie Inc. Method of Treating HCV
WO2016134058A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Combinations useful to treat hepatitis c virus
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
MX2018002461A (es) * 2015-08-28 2018-06-07 Caliway Biopharmaceuticals Co Ltd Una composicion farmaceutica para reducir la grasa localizada y sus usos.
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CA3056614C (en) 2017-03-15 2023-09-26 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
IL283450B2 (en) * 2018-11-30 2024-06-01 Chemocentryx Inc Solid solution capsule formulations containing (3S,2R)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-N-(4-methyl-3-(trifluoromethyl)phenyl) Piperidine-3-carboxamide, methods for their preparation and their medical uses
WO2023154171A1 (en) * 2022-02-14 2023-08-17 Purdue Research Foundation Polymer salts for improved drug delivery from amorphous solid dispersions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
WO2004093915A1 (en) * 2003-04-02 2004-11-04 Boehringer Ingelheim International, Gmbh Pharmaceutical compositions for hepatitis c viral protease inhibitors
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
CN1274300C (zh) * 2003-12-11 2006-09-13 中国科学院生物物理研究所 用于改善姜黄素溶出度和生物利用度的药物组合物及其制备方法
US20060068007A1 (en) * 2004-09-24 2006-03-30 Boehringer Ingelheim Pharmaceuticals, Inc. Class of surfactant-like materials
TW200716631A (en) * 2005-05-12 2007-05-01 Tibotec Pharm Ltd Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
TWI383980B (zh) * 2005-07-29 2013-02-01 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑
UY30437A1 (es) * 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
AU2008340430B2 (en) * 2007-12-21 2013-01-24 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
JP2011519364A (ja) * 2008-04-15 2011-07-07 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
JP2011530532A (ja) * 2008-08-07 2011-12-22 シェーリング コーポレイション 固体分子分散物中のｈｃｖプロテアーゼインヒビターの薬学的処方物
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP2346329B1 (en) * 2008-10-09 2013-08-21 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
US8232246B2 (en) * 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
US8476225B2 (en) * 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
ES2613608T3 (es) 2017-05-24
SG183985A1 (en) 2012-10-30
CN103118681B (zh) 2015-02-18
CA2792601A1 (en) 2011-09-15
WO2011112558A2 (en) 2011-09-15
DOP2012000245A (es) 2013-02-15
TWI490218B (zh) 2015-07-01
JP2015145387A (ja) 2015-08-13
BR112012022774A2 (pt) 2017-09-12
CN104771364B (zh) 2018-05-25
AU2011224558A1 (en) 2012-09-27
KR101579079B1 (ko) 2015-12-21
MX2012010478A (es) 2013-02-01
MY156888A (en) 2016-04-15
PE20130198A1 (es) 2013-03-24
EA201290892A1 (ru) 2013-03-29
GT201200257A (es) 2014-09-26
CO6640208A2 (es) 2013-03-22
CN103118681A (zh) 2013-05-22
TW201202239A (en) 2012-01-16
KR20130048210A (ko) 2013-05-09
CA2792601C (en) 2015-09-29
NZ602288A (en) 2014-02-28
IL221833A (en) 2017-01-31
ECSP12012148A (es) 2012-10-30
JP5890553B2 (ja) 2016-03-22
EP2544689A2 (en) 2013-01-16
CL2012002500A1 (es) 2012-12-07
AU2011224558B2 (en) 2014-02-27
UY33265A (es) 2011-10-31
EP2544689A4 (en) 2014-04-02
AR081736A1 (es) 2012-10-17
US20110312973A1 (en) 2011-12-22
JP2013522208A (ja) 2013-06-13
EP2544689B1 (en) 2017-01-11
ZA201207093B (en) 2013-05-29
CN104771364A (zh) 2015-07-15
EA021570B1 (ru) 2015-07-30
JP5717768B2 (ja) 2015-05-13
WO2011112558A3 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
UA104517C2 (uk) Тверда композиція, що є корисною в лікуванні інфекції вірусу гепатиту с, та способи її одержання
MY164607A (en) Solid compositions
MX2014008008A (es) Composiciones solidas que comprenden un inhibidor del virus de la hepatitis c.
HK1166788A1 (uk)
WO2011091322A3 (en) Antimicrobial agent comprising peroxide, alcohol and chelating agent
WO2013173506A3 (en) Kinase inhibitors for use in the treatment of muscular degradation
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
WO2010094009A3 (en) Methods and compositions for the treatment of ras associated disorders
IN2012DN03883A (uk)
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MY181898A (en) Heterocyclic compounds and uses thereof
WO2008153610A3 (en) Use of il-23 antagonists for treatment of infection
MX2012002925A (es) Inhibidores de virus flaviviridae.
WO2012090043A8 (en) Novel solid state forms of azilsartan medoxomil and preparation thereof
WO2010017368A3 (en) Methods and compositions for treating anxiety
WO2007101710A8 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
WO2010032011A3 (en) Anti-fungal therapy
MY156963A (en) Ethanol compositions
MA37650A1 (fr) Forme amorphe d'un composé pyrimidinyl-cyclopentane inhibiteur de akt, compositions et procédés de celle-ci
WO2012017321A3 (en) Treatment for dyslipidemia
WO2012018932A3 (en) Compounds and compositions for mitigating tissue damage and lethality
WO2010055474A3 (en) Antimicrobial compounds and compositions
MY192606A (en) Solid pharmaceutical compositions for treating hcv
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv